Partners in the Continuum of Drug Development with Gabriele Brambilla AliraHealth

Gabriele Brambilla is the CEO and Executive VP of AliraHealth and is looking for ways to humanize healthcare and involve patients in the entire drug development continuum. They deliver services to drug developers, medical device developers, and digital health solution providers. Gabriele explains, "We call it democratization of life sciences research, the ability to use our technology to directly involve patients, in different phases of development of a drug or a device, in a very active partnership, not just a passive collection of data." "So AliraHealth provides a continuum of services that starts from the very early phases of development of a drug or a device. And a drug would be for us the CMC, which is chemistry manufacturing control. It would go then to regulatory, so we help our clients to interact with the FDA, or EMA for Europe, and then register the drugs. And we run clinical trials for our clients and market access. Also the ability to deliver value and effectiveness in front of payers so that they can actually reimburse for the drug and give access to patients to the drug." @AliraHealth #PatientCentric #DigitalHealth #DecentralizedClinicalTrials #Digitaltx #DrugDevelopment AliraHealth.com Download the transcript here